End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.92 CNY | -1.40% | -1.60% | -10.38% |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company shows low valuation levels, with an enterprise value at 0.41 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.38% | 1.09B | - | ||
-1.20% | 66.01B | A- | ||
+47.62% | 41.76B | B | ||
+15.99% | 38.66B | B | ||
+4.25% | 32.28B | A- | ||
+8.78% | 19.57B | B- | ||
+12.32% | 16.77B | C+ | ||
+17.69% | 15.08B | B- | ||
+8.31% | 14.83B | B | ||
-14.59% | 13.95B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 000059 Stock
- Ratings North Huajin Chemical Industries Co.,Ltd